Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vimian Group AB ( (SE:VIMIAN) ) just unveiled an announcement.
Vimian Group AB has initiated the subscription period for its 2022-2025 incentive program, allowing employees to subscribe to shares through a warrant program. To support this, some warrant holders have sold shares, and Vimian’s major shareholder, Fidelio Vet Holding AB, facilitated the process by lending shares to the investment bank handling the transaction. This strategic move aims to enhance liquidity and ensure a smooth subscription process for both local and foreign warrant holders, maintaining Fidelio’s shareholding position.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company that operates in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company aims to provide top-tier care for animals by offering innovative solutions to veterinary professionals and pet owners. Based in Stockholm, Sweden, Vimian serves over 17,000 veterinary clinics and laboratories across more than 80 markets, with a workforce of 1,200 employees and annual revenues of approximately EUR 375 million.
Average Trading Volume: 494,797
Current Market Cap: SEK20.87B
Find detailed analytics on VIMIAN stock on TipRanks’ Stock Analysis page.